Circulating epigenetic signatures classifying brain insulin resistance in humans.

Journal: Science translational medicine
Published Date:

Abstract

Brain insulin action plays an important role in metabolic and cognitive health, but there is no biomarker available to assess brain insulin resistance in humans. Here, we developed a machine learning framework based on blood DNA methylation profiles of participants who did not have type 2 diabetes with and without brain insulin resistance and detailed metabolic phenotyping. We identified 540 DNA methylation sites (CpGs) as classifiers of brain insulin resistance in a discovery cohort ( = 167), results that were validated in two replication cohorts ( = 33 and 24) with high accuracy (83 to 94%). All 540 CpGs were differentially methylated and annotated to 445 genes mapping to neuronal development and axonogenesis processes. Methylation patterns of 98 of 540 CpGs exhibited a strong and significant ( < 0.05) blood-brain correlation, indicating that blood cells are a reliable proxy to capture brain-specific DNA methylation changes. These blood-based epigenetic signatures could potentially serve in the future for the early detection of individuals with brain insulin resistance in a broad clinical setting.

Authors

  • Stephanie Kullmann
    Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen, 72076, Tübingen, Germany.
  • Amandeep Singh
    Associate Professor, Department of Public Health Dentistry, NIMS Dental College, Jaipur.
  • Ratika Sehgal
    German Center for Diabetes Research (DZD), 85764, München-Neuherberg, Germany.
  • Fabian Eichelmann
    German Center for Diabetes Research (DZD), 85764, München-Neuherberg, Germany.
  • Leontine Sandforth
    Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen, 72076, Tübingen, Germany.
  • Britta Wilms
    German Center for Diabetes Research (DZD), 85764, München-Neuherberg, Germany.
  • Markus Jähnert
    German Center for Diabetes Research (DZD), 85764, München-Neuherberg, Germany.
  • Andreas Peter
    Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen, 72076, Tübingen, Germany.
  • Svenja Meyhöfer
    German Center for Diabetes Research (DZD), 85764, München-Neuherberg, Germany.
  • Dirk Walther
    Max Planck Institute of Molecular Plant Physiology, Am Mühlenberg 1, 14476, Potsdam, Golm, Germany.
  • Hubert Preissl
    Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich, University of Tübingen, Tübingen, Germany.
  • Hans-Ulrich Häring
    Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich, University of Tübingen, Tübingen, Germany.
  • Matthias B Schulze
    Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
  • Martin Heni
    Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich, University of Tübingen, Tübingen, Germany.
  • Andreas L Birkenfeld
    Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich, University of Tübingen, Tübingen, Germany.
  • Annette Schürmann
    German Center for Diabetes Research (DZD), 85764, München-Neuherberg, Germany.
  • Meriem Ouni
    German Center for Diabetes Research (DZD), 85764, München-Neuherberg, Germany.